EICHORCondition: Marginal Zone Lymphoma · Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The general aim of the present study is to assess the role of PET for the staging and for the assessment of response and outcome prediction in Marginal Zone Lymphoma (MZL). This study will be conducted as a multicenter retrospective analysis of MZL for whom PET scan are available as DICOM file for central review. The study is designed as a retrospective collection of patients with MZL enrolled in the prospective IELSG36 and IELSG38 trials sponsored by IELSG and in the observational NF10 study sponsored by Federazione Italiana Linfomi (FIL), with the possibility to add additional cases from participating institutions. The study will be conducted on performed scans. No additional scan or procedure will be required for study purposes. The study will be divided into two sections with different aims: Part A will be conducted to understand the role of PET for the staging of MZL. PET scans will be analyzed and compared with data retrieved from CT scan and from other staging procedures, also including bone marrow biopsy, ultrasound, and laboratory exams. This part of the study will describe ability of PET to identify pathologic lesions and to contribute to staging definition or to stage migration. Part B will be conducted to validate standardized criteria for response assessment in MZL including FDG-PET among procedures and to define the prognostic role of metabolic response in MZL. For this purpose the primary endpoint for this part of the study is defined as the progression fr…
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| CHU de Dijon | Dijon, France | — |
| Saint Louis Hospital | Paris, France | — |
| IUCT Oncopole Toulouse | Toulouse, France | — |
| ASO SS. Antonio e Biagio e C. Arrigo | Alessandria, AL, Italy | — |
| Ospedale degli Infermi | Ponderano, BI, Italy | — |
| Ospedale Oncologico Businco | Cagliari, CA, Italy | — |
| "G. Rodolico", AOU Policlinico Vittorio Emanuele | Catania, CT, Italy | — |
| Fondazione IRCCS - Cà Granda Ospedale Maggiore Policlinico | Milan, MI, Italy | — |
| Ospedale San Raffaele | Milan, MI, Italy | — |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, MI, Italy | — |
| AOU Policlinico "Paolo Giaccone" | Palermo, PA, Italy | — |
| I.R.C.C.S. Istituto Oncologico Veneto | Padova, PD, Italy | — |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04333524